Cancer Immunotherapy
Cancer immunotherapy (CIT) is a type of biological therapy, aiming to improve anti-tumor immune responses with fewer off-target effects than chemotherapy. Several types of immunotherapy include: oncolytic virus therapies, cancer vaccines, cytokine therapies, adoptive cell transfer (ACT), and immune checkpoint inhibitors (ICIs). In particular, ICIs and ACT have obtained immense clinical response, but their efficacy varies from person to person. Immune cells can be harnessed to eliminate tumor cells, such as T cells, B cells, NK cells, and myeloid cells. T cells have potent tumor-killing capability, therefore, a plethora of cancer immunotherapy research have focused on inducing T-cell-mediated anti-tumor responses. CTLA-4 and PD-1 are found on the cell surface of T cells as co-inhibitory receptors. The breakthrough in cancer immunotherapy results from the identification and subsequent targeting of checkpoint mechanisms in T cells with monoclonal antibodies against CTLA-4 and programmed death-ligand 1/programmed death-1 (PD-L1/PD-1).
Several types of cancers (e.g., melanoma, mismatch repair-deficient cancers, bladder cancer, and non-small cell lung cancer) have achieved significant clinical responses in T-cell checkpoint blockade therapies. However, single-mode immunotherapy faces challenges such as low immune response, low tumor infiltration, and complex immunosuppressive tumor microenvironment. Recently, combined therapies based on tumor immunity have received extensive attention in the research of enhancing tumor cells immunogenicity and inhibiting their growth. For example, anti CTLA-4 and PD-1, immune checkpoint blockade (ICB) combined with chemotherapy, anti-angiogenic drugs and kinase inhibitors.
-
BCL6 PROTAC 1
0 ImagesCat. No.: HY-122829CAS No.: 2257479-54-0
-
PARP1-IN-49
0 ImagesCat. No.: HY-179406PARP1-IN-49 is a selective PARP1 inhibitor with an IC50 of 23.56 nM and a Kd of 17.78 nM. PARP1-IN-49 shows a selectivity for PARP1 over PARP2. PARP1-IN-49 leads to the induction of DNA damage, cell cycle arrest, and apoptosis. PARP1-IN-49 also increases intracellular ROS levels and inhibits cell migration. PARP1-IN-49 can be used for the research of breast cancer and ovarian cancer.
-
Fmoc-Val-Cit-PAB (GMP)
0 ImagesCat. No.: HY-19318GCAS No.: 159858-22-7Fmoc-Val-Cit-PAB GMP is a GMP grade Fmoc-Val-Cit-PAB (HY-19318). Fmoc-Val-Cit-PAB is a cleavable antibody-conjugated active molecule (ADC) commonly used linker.
-
Melafolone
0 ImagesCat. No.: HY-165394CAS No.: 129724-42-1Melafolone is a potent dual COX-2/EGFR inhibitor with IC50s of 13.2 μM (COX-2) and 17.4 μM (EGFR). Melafolone enhances the effect of anti-PD-1 through vascular normalization and PD-L1 downregulation via the PI3K/Akt pathway in Lewis lung carcinoma (LLC) and CMT167 models. Melafolone can be used for lung cancer research.
-
BCN-PEG4-HyNic
0 ImagesCat. No.: HY-136061CAS No.: 1507370-54-8BCN-PEG4-HyNic is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). BCN-PEG4-HyNic is a click chemistry reagent, it contains a BCN group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
-
FAP-IN-9
0 ImagesCat. No.: HY-182272FAP-IN-9 (compound P12) is a fibroblast activation protein (FAP) inhibitor with an IC50 of 0.38 nM against human FAP. FAP-IN-9 functionally inhibits FAP activity, and its specific binding is verified by in vitro and in vivo blocking assays. FAP-IN-9 forms stable complexes and acts as a tumor-targeting agent. When labeled with 99mTc, FAP-IN-9 serves as a SPECT probe and is applicable to research related to glioblastoma.
-
Amprenavir-d4-1
0 ImagesCat. No.: HY-17430S1CAS No.: 2738376-78-6Synonyms: VX-478-d4-1
-
YW-N-7 TFA
0 ImagesCat. No.: HY-170855AYW-N-7 TFA is a PROTAC degrader targeting RET kinase, with an IC50 of 8.4 nM. YW-N-7 TFA inhibits RET kinase activity and induces proteasome-mediated degradation of RET fusion proteins, while enhancing the anti-tumor activity of Selpercatinib (LOXO-292) (HY-114370). YW-N-7 TFA can be used in the research of cancers associated with RET gene abnormalities, including medullary thyroid carcinoma, papillary thyroid carcinoma and non-small cell lung cancer.
-
Edultin
0 ImagesCat. No.: HY-N19810CAS No.: 15591-75-0Synonyms: Libanotine; CnidimineEdultin (Libanotine; Cnidimine) is an angular furanocoumarin. Edultin potently inhibits TPA (HY-18739)-induced early signals associated with tumor promotion (phospholipid metabolism). Edultin exerts mild inhibitory effects on some clinically isolated strains of Pseudomonas aeruginosa and Staphylococcus aureus. Edultin can be used in studies related to tumor promotion and bacterial infections.
-
AurkA allosteric-IN-1
0 ImagesCat. No.: HY-158038CAS No.: 3035323-39-5AurkA allosteric-IN-1 (compound 6h) is an Aurora A (AurkA) inhibitor (IC50: 6.50 μM) that inhibits the catalytic activity and non-catalytic functions of Aurora A. Aurora A regulates the assembly of the bipolar mitotic spindle and the fidelity of chromosome segregation during mitosis and has non-catalytic functions. AurkA allosteric-IN-1 blocks the interaction of AurkA with the activator TPX2 by binding to the Y pocket of AurkA.
-
ORS-14
0 ImagesCat. No.: HY-184689CAS No.: 1311892-52-0ORS-14 is a LILRB4/ILT3 ligand with a Kd of 85.2 nM for human receptors. ORS-14 blocks SCG2-mediated LILRB4 signaling pathway, reverses SCG2-mediated immunosuppression, restores cytokine production, reduces tumor cell viability, recovers cytotoxic T cell function, and increases the frequency of granzyme B+ CD8+ T cells. ORS-14 can be used in research related to colorectal cancer and acute myeloid leukemia.
-
HPV16-E711-20 epitope
0 ImagesCat. No.: HY-P1881CAS No.: 160040-04-0HPV16-E711-20 epitope is a well-known HLA-A*0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2 in vitro. HPV16 CTL epitopes may be good candidates for the development of an effective peptide-based antitumor vaccine.
-
TrxR-IN-2
0 ImagesCat. No.: HY-132972CAS No.: 2866261-50-7TrxR-IN-2 is a thioredoxin reductase (TrxR) inhibitor. TrxR-IN-2 increases reactive oxidative species (ROS) levels and decreases mitochondrial transmembrane potential levels. TrxR-IN-2 triggers DNA damage via H2AX regulation, and induces autophagy via LC3, beclin-1, and p62 regulation. TrxR-IN-2 can be used for the research of drug-resistant hepatocellular carcinoma[1].
-
FLT3-IN-37
0 ImagesCat. No.: HY-179497FLT3-IN-37 (Compound 6z) is a potent inhibitor of FLT3-ITD, with IC50 values of 1.5 and 3.4 nM for FLT3-ITD and TEL-VEGFR2, respectively. FLT3-IN-37 exhibits high selectivity for wild-type FLT3 (WT) and c-Kit. FLT3-IN-37 inhibits FLT3 phosphorylation and downregulates the expression of p-Akt, p-STAT5, and p-ERK. FLT3-IN-37 exerts anti-leukemia effects by blocking the cell cycle and inducing apoptosis (apoptosis). FLT3-IN-37 can be used for research on acute myeloid leukemia (AML).
-
Raltegravir-13C,d3 potassium
0 ImagesCat. No.: HY-10353AS1Synonyms: MK-0518-13C,d3 potassiumRaltegravir-13C,d3 potassium is 13C labeled Raltegravir potassium (HY-10353A). Raltegravir (MK 0518) potassium is a potent integrase (IN) inhibitor, used to treat HIV infection.
-
Phomoxanthone A
0 ImagesCat. No.: HY-126640CAS No.: 359844-69-2Phomoxanthone A is a xanthone dimer, which can be isolated from Phomopsis. Phomoxanthone A exhibits antimalarial and antitubercular activities against Plasmodium falciparum (K1, multidrug-resistant strain, IC50 is 0.11 µg/mL) and Mycobacterium tuberculosis (H37Ra strain, MIC is 0.50 µg/mL). Phomoxanthone A exhibits cytotoxicity in cells KB, BC-1 and Vero, IC50 is 0.99, 0.51 and 1.4 µg/mL, respectively.
-
Anti-Mouse CD132 (common γ chain) Antibody (3E12)
0 ImagesCat. No.: HY-P990292Anti-Mouse CD132 (common γ chain) Antibody (3E12) is a rat-derived IgG2b type antibody inhibitor, targeting to mouse CD132. Anti-Mouse CD132 (common γ chain) Antibody (3E12) can block IL-2, IL-4 and IL-7. Anti-Mouse CD132 (common γ chain) Antibody (3E12) can inhibit T cells and B cells. Anti-Mouse CD132 (common γ chain) Antibody (3E12) can be used for the researches of cancer, immunology, inflammation and metabolic disease, such as tumor, skin transfer and diabetes.
-
Loxoprofen sodium (Standard)
0 ImagesLoxoprofen (sodium) (Standard) is the analytical standard of Loxoprofen (sodium). This product is intended for research and analytical applications. Loxoprofen sodium is a non-steroidal, orally active anti-inflammatory agent with analgesic and anti-pyretic properties. Loxoprofen sodium is a nonselective COX inhibitor with IC50s of 6.5 and 13.5 μM for COX-1 and COX-2, respectively. Loxoprofen sodium can reduce atherosclerosis and shows antitumor activity.
-
Aminooxy-PEG2-bis-PEG3-BCN
0 ImagesCat. No.: HY-136089Aminooxy-PEG2-bis-PEG3-BCN is a cleavable 5 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Aminooxy-PEG2-bis-PEG3-BCN is a click chemistry reagent, it contains a BCN group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
